Encorafenib and Cetuximab in Patients With Metastatic, BRAFV600E-mutated, Colorectal Carcinoma: a Multi-centric, Multi-national, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Cetuximab (Primary) ; Encorafenib (Primary)
- Indications Cancer metastases; Carcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms BERING CRC
- Sponsors Pierre Fabre
- 04 Jun 2024 Results (n=100) assessing effectiveness of Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 01 Jul 2023 Results (n=120) data collected at 56 sites across Germany, Austria, and Switzerland between 09/2020 and 11/2022, presented at the 25th World Congress on Gastrointestinal Cancer
- 21 Jan 2023 Planned number of patients changed from 500 to 300.